Arcellx Cell Therapies for Cancer and Autoimmune Diseases
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies. Read More. Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma. Read More.
News - Arcellx
Feb 29, 2024 · At Arcellx, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. ... News: Quarterly Reports: Annual Reports: SEC Filings: End of Day Stock Quote: Events & Presentations ...
Investor Relations - Arcellx
Aug 8, 2024 · Latest News. 11/05/2024. Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress …
Our Pipeline, Focus Areas, and Clinical Trials - Arcellx
Arcellx Presents Phase 1 Study Of CART-ddBCMA For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients at the 2023 ASH Annual Meeting
Our Company, Story, and Leadership Team - Arcellx
Arcellx received IND approval from the FDA for ACLX-001, a controllable cell therapy that uses the ARC-SparX platform for the treatment of multiple myeloma. JUNE 2021. Arcellx secures Series C funding to continue advancing anitocabtagene autoleucel and ACLX-001. 2022.
Events & Presentations - Arcellx
Arcellx October 2024 Corporate Presentation. Download PDF of the presentation, Arcellx October 2024 Corporate Presentation. (opens in new window) 05/09/2024. iMMagine-3 Multi-center, Global, Phase 3 Randomized Control Clinical Trial Design.
Arcellx Presents Continued Robust Long-Term Responses from its …
Dec 13, 2021 · Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition. — Two dose levels studied (100 and 300 million CAR+ T-cells); MTD not reached —.
Arcellx Announces Presentation of Positive Clinical Results from ...
GAITHERSBURG, Md., June 4, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, announced the presentation of positive clinical data from the first 12 evaluable patients treated in the ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma.
Financials - SEC Filings - Arcellx
Oct 22, 2024 · At Arcellx, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. ... News: Quarterly Reports: Annual Reports: SEC Filings: End of Day Stock Quote: Events & Presentations ...
Stock Info - Arcellx
View stock chart as data table. The chart shows company stock prices from begin year to present. The chart has 2 X axes displaying Time, and navigator-x-axis. The chart has 3 Y axes displaying values, values, and navigator-y-axis.